The global “Idiopathic Inflammatory Myopathy Treatment” market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights™ published this information in an upcoming report, titled, “Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing Autoimmune Myopathy (NAM), Others), By Treatment (Corticosteroids, Immunosuppressants, Intravenous Immunoglobulins, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026.”
Leading Players operating in the Idiopathic Inflammatory Myopathy Treatment Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Grifols, S.A.
- ImmunoForge
- Shire (Takeda Pharmaceutical Company Limited)
- ORPHAZYME A/S
- Mylan N.V.
- Biotest AG
- Pfizer Inc.
- CSL Limited (CSL Behring)
- LFB Group
- Kedrion S.p.A.
- Other key market players
For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/industry-reports/idiopathic-inflammatory-myopathy-treatment-market-100198
North America Will Dominate Backed by New Product Launches
The market is geographically divided into Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific. Out of these, North America generated USD 312.4 million idiopathic inflammatory myopathy treatment market revenue in 2018. It is anticipated to dominate the market during the forthcoming years. This growth is attributable to the rising number of new product launches and the rising incidence of several types of myositis. Apart from these, increasing medical expenditure and rising research and development activities in the region would drive growth. Besides, growing technological advancements and increasing awareness programs are likely to affect the market in North America positively.
Asia Pacific is projected to exhibit the highest market value in the coming years owing to the increasing awareness campaigns about various forms of myopathies. Additionally, rising disposable income of the masses is, in turn, causing high healthcare expenditure. In advanced Asian countries, such as Japan, there is a rising prevalence of myositis. These countries are also utilizing advanced therapeutics to treat the condition. Europe is expected to showcase a considerable growth on account of the rising incidence of myopathies in multiple countries.
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Idiopathic Inflammatory Myopathy by Key Countries, 2018
- Advancements in Research & Development of Treatment Options
- Pipeline Analysis
- Key Industry Developments
- New Product Launches
- Global Idiopathic Inflammatory Myopathy Treatment Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Disease Type
- Dermatomyositis (DM)
- Polymyositis (PM)
- Inclusion Body Myositis (IBM)
- Necrotizing Autoimmune Myopathy (NAM)
- Others
